{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-012895","form_type":"8-K","ticker":"INFU","cik":"0001337013","company_name":"InfuSystem Holdings, Inc","filed_at":"2026-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.878016+00:00","generated_at":"2026-05-15T22:59:55.211948+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"InfuSystem reports record 2025 revenue $143.4M, adj. EBITDA $31.5M, net leverage 0.52x","bullets":["2025 net revenue $143.4M, up 6.3% YoY from $134.9M; seven consecutive years of record revenue.","2025 adjusted EBITDA of $31.5M (21.9% margin) vs $25.3M (18.8%) in 2024; cash flow from operations $24.4M.","Patient Services revenue $86.5M (60% of total), Device Solutions $56.9M (40%); gross margin 56.0%.","Share repurchase program: $11.0M bought back through Dec 31, 2025; $20M authorization expires June 2026.","Net leverage 0.52x, debt/equity 0.75x, total available liquidity $58.2M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-012895","json":"https://secwatch.observer/filing/0001628280-26-012895.json","markdown":"https://secwatch.observer/filing/0001628280-26-012895.md","text":"https://secwatch.observer/filing/0001628280-26-012895.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1337013/000162828026012895/0001628280-26-012895-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1337013/000162828026012895/infu-20260227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:59:55.211948+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}